Cited 9 times in
Combinations containing amoxicillin–clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2015-06-10T12:38:35Z | - |
dc.date.available | 2015-06-10T12:38:35Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110182 | - |
dc.description.abstract | BACKGROUND: The purpose of the present paper was to evaluate the efficacy and tolerability of amoxicillin-clavulanate and tetracycline-based quadruple therapy as an alternative second-line treatment for H. pylori infection. METHODS: The study subjects consisted of 54 patients infected with H. pylori, in whom initial triple therapy had failed. Subjects were randomized to receive the following 7-day therapies: (i) pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., amoxicillin-clavulanate 1000 mg b.i.d., and tetracycline 500 mg q.i.d. (PBAT); or (ii) pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. (PBMT). Eradication rates based on antibiotic susceptibility, drug compliance and side-effect rates were evaluated and compared. RESULTS: The H. pylori eradication rates were 16.0%/17.4% with PBAT and 65.5%/70.4% with PBMT by intention-to-treat (P<0.001) and per-protocol analyses (P<0.001), respectively. In patients who received PBAT, the eradication rates were only 16.7% (2/12) for both amoxicillin and tetracycline-susceptible H. pylori strains. Drug compliance and side-effect rates were similar in the two groups. CONCLUSIONS: Despite high individual in vitro antimicrobial activity, amoxicillin-clavulanate and tetracycline-based quadruple therapy showed low eradication rates, which strongly suggests that it should not be considered as a therapeutic option for H. pylori eradication. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1590~1595 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use | - |
dc.subject.MESH | Amoxicillin-Potassium Clavulanate Combination* | - |
dc.subject.MESH | Anti-Bacterial Agents* | - |
dc.subject.MESH | Anti-Ulcer Agents/therapeutic use | - |
dc.subject.MESH | Biopsy | - |
dc.subject.MESH | Bismuth/therapeutic use | - |
dc.subject.MESH | Contraindications | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Endoscopy, Gastrointestinal | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Helicobacter Infections/drug therapy* | - |
dc.subject.MESH | Helicobacter Infections/microbiology | - |
dc.subject.MESH | Helicobacter Infections/pathology | - |
dc.subject.MESH | Helicobacter pylori/drug effects | - |
dc.subject.MESH | Helicobacter pylori/isolation & purification* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Metronidazole/therapeutic use | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organometallic Compounds/therapeutic use | - |
dc.subject.MESH | Pantoprazole | - |
dc.subject.MESH | Pyloric Antrum/microbiology* | - |
dc.subject.MESH | Pyloric Antrum/pathology | - |
dc.subject.MESH | Stomach Ulcer/drug therapy | - |
dc.subject.MESH | Stomach Ulcer/microbiology | - |
dc.subject.MESH | Stomach Ulcer/pathology | - |
dc.subject.MESH | Tetracycline* | - |
dc.subject.MESH | Treatment Failure | - |
dc.title | Combinations containing amoxicillin–clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.contributor.googleauthor | Sang Gyun Kim | - |
dc.contributor.googleauthor | Jung Mogg Kim | - |
dc.contributor.googleauthor | Nayoung Kim | - |
dc.contributor.googleauthor | Dong Ho Lee | - |
dc.contributor.googleauthor | Joo Sung Kim | - |
dc.contributor.googleauthor | Hyun Chae Jung | - |
dc.contributor.googleauthor | In Sung Song | - |
dc.identifier.doi | 10.1111/j.1440-1746.2006.04291.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 16928222 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2006.04291.x/abstract | - |
dc.subject.keyword | amoxicillin–clavulanate | - |
dc.subject.keyword | Helicobacter pylori | - |
dc.subject.keyword | quadruple | - |
dc.subject.keyword | tetracycline | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 21 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1590 | - |
dc.citation.endPage | 1595 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.21(10) : 1590-1595, 2006 | - |
dc.identifier.rimsid | 52549 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.